immunogenicity
Immunogenicity: Unwanted!
April 13 by Pharma IQThe journey from drug design to market can be a long and arduous one, with several obstacles to overcome, and immunogenicity is one which has derailed many applications. Unwanted immunogenicity c...
FDA to Address Industry Questions about Biosimilar Regulations at the Pharma's IQ Immunogenicity Event
April 04 by Pharma IQ NewsThis May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's Immunogenicity event to discuss FDA directives on Immu...
Latest News from the Immunogenicity Studies Front
March 14 by Pharma IQImmunogenicity is a complex series of responses to a foreign substance, the production of neutralising and non-neutralising antibodies and immune complexes, and different reactions and responses. Sc...
Adverse Immune Effects of Nanomedicines and Biologicals– Under the Microscope
March 02 by Helen WinsorJanos Szebeni, Director of the Nanomedicine Research and Education Center, Bay Zoltan Foundation for Applied Research at Semmelweis University, Budapest, joins Helen Winsor Pharma IQ, to discuss dev...
Assay Development and Immunogenicity Testing
February 25 by Pharma IQImmunogenicity is becoming an integral feature within drug development activities. Testing immunogenicity, however, presents those within the pharmaceutical industry with a host of challenges; ones w...
Assessment of Unwanted Immunogenicity
February 21 by Pharma IQUnwanted immunogenicity can often result in projects being cancelled or severely delayed, to the substantial cost of the developer, and so ensuring this particular process goes smoothly is at the fore...
Pharmaceutical Firms Make Immunogenicity a Priority
June 08 by Pharma IQInterest in immunogenicity is growing among pharmaceutical companies. The concept – which measures the potential for a drug to trigger the body's immune system – has been prominent...
Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins
May 18 by Pharmaceuticals & Biotechnology EditorDRAFT GUIDANCE: This guidance provides recommendations to facilitate industry’s development of immune assays for assessment of the immunogenicity of therapeutic proteins during Clinical Trials...
The Technological Approach to Immunogenicity
May 11 by Pharma IQWhen it comes to drug development, immunogenicity is one concept that has risen up the agenda for pharmaceutical companies in the past few years. Much investment has been placed into improving the pot...